Core Insights - Molecular Partners AG is presenting updated data from a Phase 1/2a trial of MP0533, a novel T cell engager for acute myeloid leukemia (AML) patients, at the upcoming ASH Annual Meeting [1][2] Group 1: Clinical Trial Details - The trial is a first-in-human, multicenter, open-label study evaluating MP0533 in relapsed/refractory AML and myelodysplastic syndrome (MDS)/AML patients [2] - MP0533 demonstrates an acceptable safety profile across dosing regimens DR 1–9, with preliminary signs of antitumor activity being encouraging [2] - The study is currently administering doses to patients in DR 10 [2] Group 2: Mechanism of Action - MP0533 is a tetra-specific T cell-engaging DARPin that targets three tumor-associated antigens (CD33, CD123, CD70) on AML cells and the immune activator CD3 on T cells [3] - The design allows MP0533 to preferentially bind to AML cells over healthy cells, enhancing T cell-mediated killing while minimizing damage to healthy cells [3] Group 3: Presentation Details - The presentation will occur on December 7, 2025, during the session focused on investigational drugs and cellular therapies for acute myeloid leukemias [4] - The full abstracts will be available on the ASH website starting November 3, 2025 [4] Group 4: About DARPin Therapeutics - DARPin therapeutics represent a new class of custom-built protein drugs that offer multi-functionality and multi-target specificity [5] - The platform is designed for rapid and cost-effective drug discovery, producing candidates with optimized properties and high production yields [5] Group 5: About Molecular Partners AG - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, primarily in oncology [6] - The company has various programs in different stages of development and collaborates with leading pharmaceutical companies [6]

Core Insights - Corbion has reported the details of its share buyback program initiated on 1 September 2025, indicating a significant commitment to returning value to shareholders [1] - As of the week ending 31 October 2025, a total of 102,003 shares were repurchased at an average price of €17.6450, amounting to €1,799,838.05 [1] - The total number of shares repurchased to date stands at 420,203, which represents 72.40% of the overall share buyback program [1] Weekly Updates - Corbion provides a weekly overview of the share buyback program every Monday on its website, detailing the daily amount of repurchased shares and individual transactions [2]

Core Insights - Ensurge and Corning have entered into a Joint Development Agreement to create ultra-high energy density solid-state microbatteries [1][2] - The collaboration aims to integrate Corning's Ribbon Ceramic materials with Ensurge's microbattery technology to enhance performance for various applications [2][3] - This partnership is seen as a strategic milestone for Ensurge, leveraging Corning's materials science expertise to advance microbattery technology [3] Company Overview: Ensurge - Ensurge specializes in solid-state microbattery technology, focusing on high-performance and safety for AI-enabled devices [4] - The company operates from San Jose, California, and utilizes high-precision roll-to-roll production lines for its thin-film batteries [4] - Ensurge collaborates with global customers to expedite the market introduction of AI-driven products and is listed on the Oslo Stock Exchange [4] Company Overview: Corning Incorporated - Corning is a leader in materials science with a 170-year history of innovation, focusing on glass, ceramics, and optical physics [5] - The company emphasizes sustained investment in research, development, and engineering to create transformative products across various industries [5] - Corning's market presence spans optical communications, mobile consumer electronics, display technologies, automotive, solar, semiconductors, and life sciences [5]

Core Points - Ensurge Micropower ASA has entered into agreements with Corning Incorporated to develop ultra-high performance solid-state microbatteries [1][2] - The collaboration aims to integrate Corning's materials science expertise with Ensurge's microbattery technology for high-volume applications [2][3] - Corning will provide engineering resources, with costs convertible into shares of Ensurge at a predetermined price [5][6] Joint Development Agreement - The Joint Development Agreement establishes a framework for collaboration between Ensurge and Corning [2] - The goal is to commercialize batteries for consumer, medical, industrial, and defense applications [2][3] Investment Agreement - An Investment Agreement has been established, allowing Corning to invest in Ensurge [4] - Corning's investment will be convertible into new shares at a price of NOK 1.11 per share, with a maximum conversion amount of USD 5 million [5][6] Warrants - Corning will receive warrants allowing for an additional investment of up to USD 10 million at an exercise price of NOK 1.50 per share [6][7] - The warrants can be exercised within two years following approval by an extraordinary general meeting [7] Company Overview - Ensurge specializes in advanced microbattery technology, focusing on high-performance and safety for AI-enabled devices [9] - The company utilizes high-precision roll-to-roll production processes for its thin-film batteries [9]

Core Insights - Faraday Future has appointed Chris Nixon Cox as a global strategic advisor to enhance investor relations, government affairs, and industrial partnerships, supporting the company's "EAI + Crypto" strategy [1][3][11] Company Overview - Faraday Future is a California-based company focused on creating a shared intelligent electric mobility ecosystem, aiming to disrupt the automotive industry with a user-centric and technology-first approach [5] - The company's flagship model, the FF91, represents its vision for luxury and innovation, while the FX strategy targets mass production models at a broader market with middle-to-low price range offerings [5] Strategic Initiatives - Mr. Cox will facilitate introductions to potential global strategic investors and enhance government engagement and policy communications [2][3] - His role is critical for accelerating the international deployment of Faraday Future's dual strategy, which combines electric automotive innovation with cryptocurrency [3][11] Leadership Background - Chris Nixon Cox has extensive experience in both public and private sectors, serving on the Board of the Richard Nixon Foundation and as CEO of Lightswitch Capital, focusing on biotechnology investments [4] - His previous roles include advising private equity clients on mergers and acquisitions and serving as Executive Director for Senator John McCain's 2008 Presidential campaign [4]

Core Insights - Faraday Future has signed a Strategic Advisory Agreement with Chris Nixon Cox to enhance its "EAI + Crypto" strategy, aiming for global expansion [2] - Vanguard's Q3 13G filing indicates it holds approximately 7.1 million shares of FFAI, reflecting a 36% increase from Q2 [3][14] - The company has secured non-refundable deposits and non-binding preorders for over 200 units of the FX Super One from three B2B partners, exceeding initial targets [4][14] Business Developments - The integration of software and hardware upgrades for the EAI F.A.C.E. production version is currently in progress, promising an enhanced user experience [5] - The company is preparing for its quarterly financial report and earnings call, with expectations to file on schedule [6] - Faraday Future participated in the ThinkEquity Conference, engaging with over 30 investors and gaining significant attention from the capital market [7] Strategic Collaborations - Soccer superstar Andrés Iniesta has become the first global owner of the FX Super One and Developer Co-Creation Officer, indicating strong brand recognition [8] - The Middle East subsidiary has received its first FX Super One deposit paid with cryptocurrency, showcasing the synergy between Web2 and Web3 ecosystems [9] Product Launch and Market Strategy - The FX 4 rear design rendering was not presented at the October 28 launch due to strategic planning, with plans to reveal it during the Los Angeles Auto Show in November [10]

Core Insights - HUTCHMED has introduced its innovative Antibody-Targeted Therapy Conjugate (ATTC) platform, which aims to redefine precision oncology through a dual-mechanism of action [1][2] - The lead candidate HMPL-A251, a selective PI3K/PIKK inhibitor, has shown promising preclinical efficacy and safety, positioning HUTCHMED's late-stage pipeline for further development [1][4] - The company is making significant progress in global and China trials, including studies for fruquintinib, surufatinib, and fanregratinib, enhancing its late-stage pipeline [1][9] ATTC Platform and Lead Candidate - The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads, providing synergistic anti-tumor activity and improved safety profiles compared to traditional antibody-drug conjugates [2][3] - HMPL-A251 is designed to target the PAM signaling pathway, which is often associated with poor prognosis in various cancers, and aims to enhance targeted delivery while minimizing systemic exposure [3][4] - Preclinical data indicates that HMPL-A251 exhibits strong anti-tumor activity, particularly in HER2-positive tumors, and shows potential for improved efficacy compared to existing therapies like trastuzumab deruxtecan [4][5] Clinical Development Plans - HUTCHMED plans to advance HMPL-A251 into clinical development in late 2025, focusing on various cancer types with different HER2 and PAM alteration statuses [5] - The company aims to explore a broader range of antibody selections and payload options to enhance treatment outcomes and overcome resistance [6] Late-stage Program Updates - The company reported significant progress in late-stage programs, including the FRUSICA-2 study for fruquintinib, which demonstrated a progression-free survival of 22.2 months compared to 6.9 months with standard treatments [9] - Recruitment for the SANOVO study in first-line EGFR-mutated non-small cell lung cancer has been completed, with further studies for surufatinib and fanregratinib also advancing [9]

Core Viewpoint - Benitec Biopharma Inc. is set to provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301, which is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD) [1]. Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines [3]. - The company utilizes a proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform that combines RNA interference with gene therapy [3]. - This platform aims to create therapeutics that can silence disease-causing genes while delivering wildtype replacement genes in a single administration [3]. - Benitec is developing therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [3]. Webcast Information - A webcast to discuss the update on the clinical study will take place on November 3, 2025, at 8:00 am EST [2].

Core Insights - Alkane Resources Limited has reported significant drilling results from its Tomingley Gold Operations, indicating potential resource expansion and high-grade gold intercepts [6][7][12] Drilling Results - The McLeans Inferred Resource has shown promising results with notable intercepts such as: - MCLUG013D: 26 metres grading 4.36 g/t Au from 112 metres, including 3.3 metres grading 22.8 g/t Au [13] - MCLUG012D: 10.7 metres grading 2.09 g/t Au from 105 metres [13] - MCLUG011D: 8 metres grading 2.33 g/t Au from 113 metres, including 0.8 metres grading 14.4 g/t Au [13] - Additional significant intercepts from the Eastern Andesite include: - MCLUG010D: 0.5 metres grading 38.9 g/t Au from 332.5 metres [14] - MCLUG007D: 8 metres grading 2.67 g/t Au from 293.2 metres, including 3.1 metres grading 4.52 g/t Au [14] Resource Estimation - The Inferred Resource at McLeans is estimated at 0.87 million tonnes grading 2.51 g/t gold for 70,000 ounces [12] - The drilling program has improved the confidence in the resource estimation by reducing the drilling pattern from 80m x 80m to 40m x 60m [14] Roswell Drilling Program - An intensive underground diamond core drilling program at the Western Monzodiorite domain at Roswell has confirmed multiple high-grade gold intercepts, including: - ROSGT001D: 9.3 metres grading 3.88 g/t Au from 157.9 metres, including 1.1 metres grading 10.5 g/t Au [18] - ROSUG440D: 6.5 metres grading 8.03 g/t Au from 166.5 metres, including 0.9 metres grading 37.3 g/t Au [19] Future Exploration Plans - Further drilling is planned to test both the Eastern and Western Andesite hosts at McLeans and to include the discovered Western Andesite into the resource estimation [15] - Surface exploration drilling is set to commence in November 2025 to explore additional underground potential [20]

Core Insights - FireFly Metals Ltd has appointed Leanne Heywood as an Independent Non-Executive Director, bringing extensive experience in the mining sector, particularly in copper marketing [1][5][6] Company Overview - FireFly Metals Ltd is an emerging copper-gold company focused on advancing the Green Bay Copper-Gold Project in Newfoundland, Canada [6][7] - The Green Bay Copper-Gold Project currently hosts a Mineral Resource of 24.4 million tonnes (Mt) of Measured and Indicated Resources at a grade of 1.7% for 400,000 tonnes (Kt) of copper equivalent (CuEq) and 34.6 Mt of Inferred Resources at a grade of 1.7% for 600 Kt CuEq [6][19] Leadership and Experience - Leanne Heywood has held significant roles in the mining industry, including a senior international copper marketing position at Rio Tinto and Chief Financial Officer of a copper mine within Rio Tinto's portfolio [2][3] - Heywood's previous directorships include positions at Deterra Royalties Limited, Snowy Hydro Limited, and Lotus Resources Limited, among others [2][3] Strategic Importance - The appointment of Heywood is expected to enhance the independence and gender diversity of the Board, which is crucial following a period of rapid growth and the company's recent addition to the S&P/ASX 300 Index [5][6] - FireFly is currently undertaking a 130,000-meter diamond drilling program to further grow its copper-gold Mineral Resource [6][7]